Geron (GERN) Expected to Announce Quarterly Earnings on Wednesday

Geron (NASDAQ:GERN) is expected to issue its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $55.2440 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 8:00 AM ET.

Geron (NASDAQ:GERN) last posted its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%.The firm had revenue of $49.04 million for the quarter, compared to the consensus estimate of $47.30 million. During the same quarter in the prior year, the business posted ($0.10) earnings per share. The business’s quarterly revenue was up 5455.6% on a year-over-year basis. On average, analysts expect Geron to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Geron Price Performance

GERN stock opened at $1.26 on Monday. The firm has a 50 day moving average of $1.32 and a 200-day moving average of $1.36. The firm has a market capitalization of $803.90 million, a P/E ratio of -9.69 and a beta of 0.57. Geron has a 12 month low of $1.09 and a 12 month high of $4.50. The company has a current ratio of 7.87, a quick ratio of 6.79 and a debt-to-equity ratio of 0.46.

Institutional Investors Weigh In On Geron

Hedge funds and other institutional investors have recently modified their holdings of the stock. Walleye Capital LLC bought a new position in Geron during the 2nd quarter worth approximately $56,000. Tower Research Capital LLC TRC lifted its position in Geron by 551.4% in the second quarter. Tower Research Capital LLC TRC now owns 78,317 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 66,294 shares during the last quarter. Prudential Financial Inc. boosted its stake in shares of Geron by 72.3% during the second quarter. Prudential Financial Inc. now owns 79,494 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 33,352 shares during the period. E Fund Management Co. Ltd. grew its holdings in shares of Geron by 12.0% in the second quarter. E Fund Management Co. Ltd. now owns 92,238 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 9,849 shares during the last quarter. Finally, XTX Topco Ltd grew its holdings in shares of Geron by 982.9% in the second quarter. XTX Topco Ltd now owns 124,522 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 113,023 shares during the last quarter. Institutional investors own 73.71% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on GERN shares. The Goldman Sachs Group assumed coverage on shares of Geron in a research report on Thursday, July 10th. They set a “sell” rating and a $1.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Geron in a research report on Friday. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $3.79.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.